Show simple item record

dc.contributor.authorInnocenti, P
dc.contributor.authorWoodward, HL
dc.contributor.authorSolanki, S
dc.contributor.authorNaud, S
dc.contributor.authorWestwood, IM
dc.contributor.authorCronin, N
dc.contributor.authorHayes, A
dc.contributor.authorRoberts, J
dc.contributor.authorHenley, AT
dc.contributor.authorBaker, R
dc.contributor.authorFaisal, A
dc.contributor.authorMak, GW-Y
dc.contributor.authorBox, G
dc.contributor.authorValenti, M
dc.contributor.authorDe Haven Brandon, A
dc.contributor.authorO'Fee, L
dc.contributor.authorSaville, H
dc.contributor.authorSchmitt, J
dc.contributor.authorMatijssen, B
dc.contributor.authorBurke, R
dc.contributor.authorvan Montfort, RLM
dc.contributor.authorRaynaud, FI
dc.contributor.authorEccles, SA
dc.contributor.authorLinardopoulos, S
dc.contributor.authorBlagg, J
dc.contributor.authorHoelder, S
dc.date.accessioned2016-11-23T10:57:57Z
dc.date.issued2016-04-28
dc.identifier.citationJournal of medicinal chemistry, 2016, 59 (8), pp. 3671 - 3688
dc.identifier.issn0022-2623
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/233
dc.identifier.eissn1520-4804
dc.identifier.doi10.1021/acs.jmedchem.5b01811
dc.description.abstractMonopolar spindle 1 (MPS1) plays a central role in the transition of cells from metaphase to anaphase and is one of the main components of the spindle assembly checkpoint. Chromosomally unstable cancer cells rely heavily on MPS1 to cope with the stress arising from abnormal numbers of chromosomes and centrosomes and are thus more sensitive to MPS1 inhibition than normal cells. We report the discovery and optimization of a series of new pyrido[3,4-d]pyrimidine based inhibitors via a structure-based hybridization approach from our previously reported inhibitor CCT251455 and a modestly potent screening hit. Compounds in this novel series display excellent potency and selectivity for MPS1, which translates into biomarker modulation in an in vivo human tumor xenograft model.
dc.formatPrint-Electronic
dc.format.extent3671 - 3688
dc.languageeng
dc.language.isoeng
dc.publisherAMER CHEMICAL SOC
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectProtein-Serine-Threonine Kinases
dc.subjectCell Cycle Proteins
dc.subjectProtein Kinase Inhibitors
dc.subjectMolecular Structure
dc.subjectProtein-Tyrosine Kinases
dc.subjectDrug Discovery
dc.titleRapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.
dc.typeJournal Article
dcterms.dateAccepted2016-03-01
rioxxterms.versionofrecord10.1021/acs.jmedchem.5b01811
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2016-04-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfJournal of medicinal chemistry
pubs.issue8
pubs.notesNo embargo
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Drug Target Discovery
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Drug Target Discovery
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Clinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Hit Discovery & Structural Design
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 1
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Medicinal Chemistry 4 (including Analytical Chemistry)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Structural Biology/Hit Discovery & Structural Design
pubs.publication-statusPublished
pubs.volume59
pubs.embargo.termsNo embargo
icr.researchteamDrug Target Discovery
icr.researchteamClinical Pharmacology & Trials (including Drug Metabolism & Pharmacokinetics Group)
icr.researchteamMedicinal Chemistry 1
icr.researchteamMedicinal Chemistry 4 (including Analytical Chemistry)
icr.researchteamHit Discovery & Structural Design
dc.contributor.icrauthorBurke, Rosemary
dc.contributor.icrauthorVan Montfort, Robert
dc.contributor.icrauthorRaynaud, Florence
dc.contributor.icrauthorLinardopoulos, Spyridon
dc.contributor.icrauthorHoelder, Swen


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0